Jul 2026· International Journal of Biological Macromolecules· pp.
153508
· 0 citations· 48 references
Medicine
TL;DR
These findings establish CTD-2566 J3.1 as a multifunctional enhancer-associated lncRNA (e-lncRNA) that orchestrates key oncogenic processes in luminal breast cancer and underscores the utility of three-dimensional culture systems to reveal context-specific lncRNA functions.
Abstract
Long non-coding RNAs (lncRNAs) are increasingly recognized as key regulators of gene expression and genome architecture in cancer. By scaffolding chromatin-modifying protein complexes and mediating enhancer-promoter communication, lncRNAs can shape transcriptional programs that sustain tumor growth. In this study, we investigated the functional role of CTD-2566 J3.1, an antisense lncRNA located within the RAD51B locus that carries enhancer-associated chromatin marks, including H3K27ac and H3K4me1, in luminal breast cancer cells. Using chromatin conformation capture experiments (4C-seq), we identified recurrent long-range chromatin interactions linking the CTD-2566 J3.1 locus to regulatory elements within three distant genes with established roles in cancer biology: RAD51B, MAP3K9, and ACTN1. These genomic regions were enriched for estrogen receptor (ESR1) and FOXA1 binding sites, suggesting hormone-responsive regulation. Interestingly, in three-dimensional spheroids, these genes were consistently more expressed than in monolayer cultures, underscoring the importance of microenvironmental context for transcriptional regulation in breast cancer. Functionally, loss of CTD-2566 J3.1 impaired cell proliferation and invasion and increased endogenous DNA damage. Our findings establish CTD-2566 J3.1 as a multifunctional enhancer-associated lncRNA (e-lncRNA) that orchestrates key oncogenic processes in luminal breast cancer. Additionally, this work underscores the utility of three-dimensional culture systems to reveal context-specific lncRNA functions and highlights CTD-2566 J3.1 as a potential regulator and therapeutic target in breast cancer.
This study uncovers a therapeutic vulnerable lncRNA-centric circuitry and provides compelling preclinical evidence for the development and application of a novel RNA targeting-LNP based therapy for treatment of myeloid leukemia.
Zhenggen Jin, Brendan D. Ma, Karen Y. T. Chan et al.· bioRxiv· 0 citations
A novel functional SNP-lncRNA axis that contributes to CRC pathogenesis is elucidated, providing potential biomarkers for early detection and therapeutic targets for intervention.
Jia-Li Ma, Xianglong Tian, Yiwen Qiu et al.· European Journal of Histoche...· 0 citations
Findings indicate that RP3-340N1.2 is aberrantly expressed in LUAD and may participate in tumor-associated cellular behaviors through a miR-4650-5p/SHC1-related regulatory mechanism.
Fang Chen, Yan Yan, Wenting Yang et al.· PLoS ONE· 0 citations
A mechanism wherein SChLAP1 modulates AR signaling to promote PCa growth and progression is suggested, suggesting its molecular mechanism and potential to be used as a therapeutic target or biomarker.
It is established that the lncRNA MNX1-AS1 acts as a crucial driver of one-carbon metabolism reprogramming in non-small cell lung cancer and highlighted that the newly identified MNX1-AS1/CACYBP/β-catenin axis may serve as a potential prognostic biomarker and therapeutic target for lung cancer intervention.
Juze Yang, Xinyi Qian, Jiayi Ren et al.· Cell Death and Differentiati...· 0 citations
It is shown that p63 reorganizes 3D chromatin topology in squamous cell carcinoma through cooperation with the tumor-selective partner TF, FOXK1, which defines an epigenetic mechanism by which a lineage master TF and tumor-restricted partner TF reshape 3D chromatin structure to drive oncogenic transcription, with impli...
N. Jung, V. Lopez-Pajares, L. Donohue et al.· Science Advances· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.